Managing Hair Loss on Zepbound (Tirzepatide): The HealthRX.com Step-by-Step Protocol

How common is hair loss on Zepbound?

The rates come from the Zepbound label, which pools two placebo-controlled weight-management trials, SURMOUNT-1 and SURMOUNT-2: 2,519 adults treated with Zepbound for up to 72 weeks and 958 on placebo [1]. Hair loss was reported by 5% of people on 5 mg, 4% on 10 mg and 5% on 15 mg, versus 1% on placebo [1]. It also appears on the label's list of common adverse reactions, meaning those reported in at least 5% of treated patients [1].

The figures do not climb steadily with dose. The rate at 10 mg is lower than at 5 mg, and the 5 mg and 15 mg rates are the same [1].

Is it the tirzepatide or the weight loss?

The label reports that hair loss was associated with weight reduction, and that it was more frequent in women [1]. Among people taking Zepbound, 7.1% of women and 0.5% of men reported hair loss, compared with 1.3% of women and 0% of men on placebo [1].

The subtype most often described is telogen effluvium. A 2026 systematic review screened 133 studies and included 24 on GLP-1 drugs and hair loss; it found telogen effluvium and androgenetic alopecia to be the predominant subtypes reported, with tirzepatide, the drug producing the largest weight losses, most often linked to telogen effluvium, and rapid weight loss a potential contributor [2]. The authors concluded that causality and the timing of the relationship still need to be established in large prospective trials [2].

Telogen effluvium is a diffuse shedding of hair that follows a physical or metabolic stress. It is not a scarring process, which is different from patchy or scar-forming hair loss.

Who reports it most?

Beyond the sex difference in the label, a 2026 cross-sectional survey of 254 people using GLP-1 drugs for weight loss (71.3% women, average age 33.3) found no significant difference in hair-loss prevalence between products (p=0.116), but severe hair loss was significantly more common among Mounjaro (43.4%) and Saxenda (42.9%) users than the other groups (p<0.001) [3]. Men were less likely than women to report hair loss (adjusted odds ratio 0.36), and Mounjaro users had higher odds of reporting it than users of the other injections (adjusted odds ratio 3.02) [3]. The survey included Mounjaro users, but it did not study Zepbound specifically [3]. The survey is self-reported, from one country, and cannot show cause.

What the label says about dose changes

Zepbound starts at 2.5 mg once weekly for 4 weeks; that is an initiation dose and is not approved as a maintenance dose [1]. Maintenance is 5, 10 or 15 mg once weekly for weight reduction, or 10 or 15 mg for obstructive sleep apnea, with a maximum of 15 mg [1]. The label says a lower maintenance dose can be considered when a maintenance dose is not tolerated; that statement is general and is not specific to hair loss [1].

In the pooled trials, hair loss did not lead any Zepbound-treated patient to stop treatment; one placebo-treated patient discontinued because of it [1]. Overall, 4.8%, 6.3% and 6.7% of patients on 5, 10 and 15 mg stopped treatment for an adverse reaction, versus 3.4% on placebo, mostly gastrointestinal reactions during the first few months [1].

What happens to weight if treatment stops?

SURMOUNT-4 is the clearest evidence on stopping. In that trial, 783 adults entered a 36-week open-label tirzepatide lead-in period, and 670 were then randomized to continue tirzepatide or switch to placebo; those 670 had lost a mean 20.9% of their body weight by week 36 [4]. From week 36 to week 88, weight changed by -5.5% in those who continued tirzepatide and by +14.0% in those who switched to placebo, a difference of 19.4 percentage points [4].

What actually helps with the hair loss?

The Zepbound label does not identify a hair-loss treatment [1]. A systematic review most frequently linked tirzepatide-related reports to telogen effluvium, but it could not establish the cause or timing of hair loss [2]. A survey of users of several GLP-1 drugs described this type of hair loss as typically non-scarring and reversible; it did not track hair regrowth in Zepbound users [3].